Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 968-975

  Rosenberg, Steven A ^a   Yang, James C ^a   Schwartzentruber, Douglas J ^a   Hwu, Patrick ^a   Marincola, Francesco M ^a   Topalian, Suzanne L ^a   Seipp, Claudia A ^a   Einhorn, Jan H ^a   White, Donald E ^a   Steinberg, Seth M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; TAMOXIFEN;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MELANOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0032976897     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.968     Document Type: Article

References (22)

1. Balch CM, Reintgen DS, Kirkwood JM, et al: Cutaneous melanoma, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1997, pp 1947-1994
2. Mastrangelo MJ, Berd D, Bellet RE: Aggressive chemotherapy for melanoma, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology: Updates, vol 5. Philadelphia, PA, Lippincott, 1991, pp 1-11
3. McClay EF, Mastrangelo MJ, Sprandio JD, et al: The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 63:1292-1295, 1989
4. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516-523, 1992
5. Marincola FM, Rosenberg SA: Melanoma, in DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1995, pp 250-262
6. Kirkwood JM: Melanoma, in DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1995, pp 388-411
7. Richards JM, Mehta N, Ramming K, et al: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 8:1338-1343, 1992
8. Antoine EC, Benhammouda A, Bernard A, et al: Salpetriere Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 3:S16-S21, 1997
9. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759, 1998
10. Kaplan E, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 50:163-170, 1966
12. Ahmann DL, Creagan ET, Hahn RG, et al: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63:224-227, 1989
13. Ryan L, Kramar A, Borden E: Prognostic factors in metastatic melanoma. Cancer 71:2995-3005, 1993
14. Del Prete SA, Maurer H, O'Donnell J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403-1405, 1990
15. Lattanzi SC, Tosteson T, Chertoff J, et al: Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 5:365-369, 1995
16. Rusthoven JJ, Quirt IC, Iscoe NA, et al: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14:2083-2090, 1996
17. Margolin KA, Liu PY, Flaherty LE, et al: Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study. J Clin Oncol 16:664-669, 1998
18. Keilholz U, Goey SH, Punt CJ, et al: Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 7:2579-2588, 1997
19. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913, 1994
20. Rosenberg SA, Yang JC, White DE, et al: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann Surg 228:307-319, 1998
21. Heywood GR, Rosenberg SA, Weber JS: Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. J Natl Cancer Inst 87:915-922, 1995
22. Shulman KL, Thompson JA, Benyunes MC, et al: Adverse reactions to intravenous contrast media in patients treated with interleukin-2. J Immunother 12:208-212, 1993